Literature DB >> 22819824

miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.

H M El Tayebi1, K A Hosny, G Esmat, K Breuhahn, Ahmed Ihab Abdelaziz.   

Abstract

microRNAs aberrant behavior in heptocellular carcinoma (HCC) plays a major role in HCC pathogenesis. miR-615-5p expression has never been evaluated in HCC. We showed that miR-615-5p was preferentially expressed in HCC, cirrhotic liver tissues and HCC cell lines, but undetected in normal livers. Forced miR-615-5p expression in HCC cell lines led to significant decrease in cell growth and migration. In-silico predication revealed insulin-like growth factor-II (IGF-II) as a potential downstream target for miR-615-5p. Forcing the expression of miR-615-5p showed downregulation of IGF-II mRNA, as well as inhibition of the luciferase activity in a luciferase reporter vector harboring the IGF-II-3'UTR target sequence. miR-615-5p acts as tumor-suppressor in HCC through targeting IGF-II.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819824     DOI: 10.1016/j.febslet.2012.06.054

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

Review 2.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

Review 3.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

Review 4.  MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine.

Authors:  Iván Lyra-González; Laura E Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  World J Hepatol       Date:  2015-06-18

5.  MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc.

Authors:  Rana Ahmed Youness; Hend Mohamed El-Tayebi; Reem Amr Assal; Karim Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  Oncol Lett       Date:  2016-07-27       Impact factor: 2.967

6.  Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.

Authors:  Danira Ashraf Habashy; Hend Mohamed El Tayebi; Injie Omar Fawzy; Karim Adel Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  World J Hepatol       Date:  2016-08-18

Review 7.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

8.  CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p.

Authors:  Yuanyuan Jiang; Yan Zhang; Fuqing Li; Xiaolin Du; Jinping Zhang
Journal:  Tumour Biol       Date:  2015-08-14

9.  miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma.

Authors:  Xiaoyu Wu; Liang Deng; Decai Tang; Gang Ying; Xuequan Yao; Fukun Liu; Gui Liang
Journal:  Tumour Biol       Date:  2015-12-10

10.  Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.

Authors:  Ping Chen; Xia Zhao; Liang Ma
Journal:  Mol Cell Biochem       Date:  2013-07-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.